Bristol Myers’s most recent trend suggests a bearish bias. One trading opportunity on Bristol Myers is a Bear Call Spread using a strike $62.00 short call and a strike $67.00 long call offers a potential 10.86% return on risk over the next 21 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $62.00 by expiration. The full premium credit of $0.49 would be kept by the premium seller. The risk of $4.51 would be incurred if the stock rose above the $67.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Bristol Myers is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Bristol Myers is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Bristol Myers
5 Brand-Name Stocks to Buy Hand Over Fist if the Market Is Tumbling
Thu, 23 Sep 2021 09:51:00 +0000
Market sell-offs are perfectly normal and an opportune time to invest in great companies at a discount.
Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA
Wed, 22 Sep 2021 12:36:12 +0000
Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.
Bristol Myers Squibb Company (BMY) Fell Out Of Favor With Hedge Funds
Wed, 22 Sep 2021 02:59:46 +0000
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
Country 2 Country 4 Cancer (C2C4C) Event
Tue, 21 Sep 2021 19:46:07 +0000
More than 150 colleagues from 14 EU countries just finished cycling 3,000 km in our Country 2 Country 4 Cancer (C2C4C) event to raise awareness and much-needed donations for cancer research. It’s m…
Bristol Myers (BMY) Opdivo-Relatlimab Combo Gets Priority Review
Tue, 21 Sep 2021 13:39:01 +0000
Bristol Myers (BMY) application for fixed-dose combination of LAG-3-blocking antibody relatlimab and immuno- oncology Opdivo gets priority review in the United States.
Follow Us on Facebook